Repibresib - Yarrow Bioscience
Alternative Names: TAY-B1; VYN-201Latest Information Update: 30 Jul 2026
At a glance
- Originator In4Derm
- Developer Tay Therapeutics; Yarrow Bioscience
- Class Anti-inflammatories; Antifibrotics; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action Bromodomain and extra-terminal domain protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Vitiligo
- Preclinical Idiopathic pulmonary fibrosis
- No development reported Inflammation; Rheumatoid arthritis; Skin disorders
Most Recent Events
- 27 Jul 2026 Yarrow Bioscience has merged with VYNE Therapeutics to form Yarrow Bioscience
- 28 Apr 2026 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Intra-articular, Injection)
- 28 Nov 2025 No recent reports of development identified for preclinical development in Inflammation in USA (Topical, Cream)